The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 8, 2018. Its latest SEC filing is a CT ORDER from Jun 26, 2020.
10-Q for Q3 FY2018, filed Nov 8, 2018
The sections below describe the company as of the FY2017 annual report.
Sells Auryxia, an oral medicine for kidney disease, to wholesalers and pharmacies serving people with kidney disease.
10-K for FY2017, filed Feb 21, 2018
It sells Auryxia to major wholesalers and certain pharmacies, offering discounts for invoices paid within 35 days. Under its Japan license, it receives license fees, milestone payments and royalties tied to partner sales.
10-K for FY2017, filed Feb 21, 2018Our commercial launch of Auryxia occurred in December 2014. We sell product to a limited number of major wholesalers, our Distributors, as…View ↗
Trade Allowances: We generally provide discounts on Auryxia sales to our Customers in the form of a discount for prompt payment of invoices…View ↗
We recognize license revenue in accordance with Accounting Standards Codification 605, Revenue Recognition. We analyze each element of our…View ↗
For arrangements for which royalty revenue information becomes available and collectibility is reasonably assured, we recognize revenue…View ↗
Auryxia is approved as a treatment for two common complications of CKD. Auryxia is a non-calcium, non-chewable, orally-administered…View ↗
$60.6M
10-K for FY2017, filed Feb 22, 2018
$60.6M ↗
Keryx sells Auryxia directly to a limited number of major wholesalers and certain pharmacies; wholesalers resell it to retail pharmacies for patient prescriptions.
10-K for FY2017, filed Feb 21, 2018Our commercial launch of Auryxia occurred in December 2014. We sell product to a limited number of major wholesalers, our Distributors, as…View ↗
10-K for FY2017, filed Feb 21, 2018
December 31, 2017 December 31, 2016 December 31, 2015 Fresenius Medical Care Rx 29 % 22 % 15 % McKesson Corporation 19 % 31 % 23 % DaVita…View ↗
No. It lost $163.4M in FY2017.
10-K for FY2017, filed Feb 22, 2018
10-Q for Q3 FY2018, filed Nov 9, 2018
−$17MView ↗
8-K, filed Dec 13, 2018
As previously announced, Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”), entered into an Agreement and Plan of Merger on…View ↗
8-K, filed Oct 25, 2018
On October 24, 2018, Keryx Biopharmaceuticals, Inc., a Delaware corporation (“Keryx”), entered into a letter agreement with Panion & BF…View ↗
8-K, filed Jun 15, 2018
(e) As previously disclosed, on April 27, 2018, Gregory P. Madison notified the Board of Directors of Keryx Biopharmaceuticals, Inc. (the…View ↗
Grew. Revenue grew 8.7x in 4 years, from $7M in FY2013 to $60.6M in FY2017, about 72% a year.
Anemia indication
Auryxia expanded from an approved treatment for high phosphorus in dialysis patients, with anemia use still in development, to also treat iron-deficiency anemia in adults with CKD who are not on dialysis.
10-K for FY2014, filed Feb 27, 2015 10-K for FY2017, filed Feb 21, 2018We are a commercial stage biopharmaceutical company focused on bringing innovative medicines to people with kidney disease. Our long-term…View ↗
Competes with Genzyme, Sanofi, Fresenius Medical Care, and Shire Pharmaceuticals Group
10-K for FY2017, filed Feb 21, 2018Auryxia is competing in the United States with other FDA-approved phosphate binders such as Renagel® (sevelamer hydrochloride) and Renvela…View ↗
Loading...
